Skip to main content
main-content

12.07.2017 | Original Article | Ausgabe 3/2017

Endocrine 3/2017

Cushing’s syndrome: a model for sarcopenic obesity

Zeitschrift:
Endocrine > Ausgabe 3/2017
Autoren:
Michael Drey, Christina M. Berr, Martin Reincke, Julia Fazel, Jochen Seissler, Jochen Schopohl, Martin Bidlingmaier, Stefanie Zopp, Nicole Reisch, Felix Beuschlein, Andrea Osswald, Ralf Schmidmaier

Abstract

Purpose

Obesity and its metabolic impairments are discussed as major risk factors for sarcopenia leading to sarcopenic obesity. Cushing’s syndrome is known to be associated with obesity and muscle atrophy. We compared Cushing’s syndrome with matched obese controls regarding body composition, physical performance, and biochemical markers to test the hypothesis that Cushing’s syndrome could be a model for sarcopenic obesity.

Methods

By propensity score matching, 47 controls were selected by body mass index and gender as obese controls. Fat mass and muscle mass were measured by bioelectrical impedance analysis. Muscle function was assessed by chair rising test and hand grip strength. Biochemical markers of glucose and lipid metabolism and inflammation (hsCRP) were measured in peripheral blood.

Results

Muscle mass did not differ between Cushing’s syndrome and obese controls. However, Cushing’s syndrome patients showed significantly greater chair rising time (9.5 s vs. 7.3 s, p = 0.008) and significantly lower hand grip strength (32.1 kg vs. 36.8 kg, p = 0.003). Cushing’s syndrome patients with impaired fasting glucose have shown the highest limitations in hand grip strength and chair rising time.

Conclusions

Similar to published data in ageing medicine, Cushing’s syndrome patients show loss of muscle function that cannot be explained by loss of muscle mass. Impaired muscle quality due to fat infiltration may be the reason. This is supported by the observation that Cushing’s syndrome patients with impaired glucose metabolism show strongest deterioration of muscle function. Research in sarcopenic obesity in elderly is hampered by confounding comorbidities and polypharmacy. As Cushing’s syndrome patients are frequently free of comorbidities and as Cushing’s syndrome is potentially curable we suggest Cushing’s syndrome as a clinical model for further research in sarcopenic obesity.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2017

Endocrine 3/2017 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise